Submission of Annual Report for the FY 2024-25 comprising of the Notice of Annual General Meeting, Directors Report, Independent Auditors Report and Audited Financial Statements (Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Royal Sense Limited, a Delhi-based medical devices and healthcare products distributor listed on the BSE SME platform, has submitted its 2nd Annual Report for FY 2024-25 ahead of its AGM scheduled for September 29, 2025 via video conferencing. On a standalone basis, revenue from operations rose to ₹2,764.31 lakhs from ₹1,896.39 lakhs, while profit after tax climbed to ₹304.49 lakhs from ₹170.19 lakhs (the company reports a 55.89% rise). On a consolidated basis, including subsidiary Stergic Retail Pvt Ltd, revenue jumped sharply to ₹6,173.40 lakhs from ₹1,780.02 lakhs, and PAT surged to ₹633.12 lakhs from ₹158.88 lakhs. EBITDA margin expanded to 14.52% from 12.91%, and return on equity rose to 24.76% from 8.72%. The company raised funds via preferential issue of 4.5 lakh convertible warrants at ₹151 each, and increased authorised capital from ₹5 crore to ₹10 crore. No dividend was declared. Statutory and secretarial auditors reported no qualifications or adverse remarks.
Strong top-line and bottom-line growth, expanding margins and a sharp jump in ROE signal healthy business momentum, which is positive for shareholders. However, the stock trades on the BSE SME platform (lower liquidity), no dividend is declared, and a proposed merger with TTG Innovations Pvt Ltd was rejected by BSE (fresh application pending), so investors should weigh execution risks.